CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ananda Developments PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ananda Developments PLC
6th Fl
Allianz House, 60 Gracechurch Street
LONDON, EC3V 0HR  United Kingdom Ticker: ANAANA
Business Summary
Ananda Developments plc is a United Kingdom-based provider of regulator approved cannabidiol (CBD)-based medicines for chronic pain conditions. The Company's main areas of focus include cannabis cultivation, trials and genetic stabilization work in its wholly owned subsidiary DJT Plants Limited (DJT) and the drug discovery process, clinical trials and market launch of various cannabis based unlicensed medicines via its 100% owned subsidiary MRX Medical Limited (MRX Medical). MRX1, MRX Medical's first product, is to be used in two Phase II Randomized Controlled Trials (RCTs) to investigate the effectiveness of CBD in chemotherapy induced peripheral neuropathy (CIPN) and in patients with endometriosis. MRX1 and MRX2, MRX Medical's second formulation, are launched as unlicensed cannabis-based products for medicinal use in humans (CBPM's). DJT growing method does not use any artificial light or heat. DJT is also undertaking a cannabis sativa genetic stabilization program.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
7/31/20241/31/2024Yes----

Industries
SIC Code Description
6282 Investment advice
6799 Investors, not elsewhere classified
6289 Services allied with the exchange of securities or commodities

General Information
Number of Employees: 5 (As of 1/31/2024)
Outstanding Shares: 2,878,027,906 (As of 7/31/2024)
Stock Exchange: AQS


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024